M. Meyer

Inhaled pan-selectin antagonist Bimosiamose attenuates airway inflammation in COPD.

H. Magnussen, H. Watz, W. Meyer-Sabellek, 2013, Pulmonary pharmacology & therapeutics.

The pharmacokinetics of subcutaneously injected bimosiamose disodium in healthy male volunteers

G. Wolff, B. Jilma, K. Vollhardt, 2007, Biopharmaceutics & drug disposition.

Late-breaking abstract: Inhaled pan-selectin antagonist bimosiamose in COPD: A double-blind, randomized, placebo-controlled phase II study

H. Magnussen, H. Watz, W. Meyer-Sabellek, 2011 .

Physiochemical properties, safety and pharmacokinetics of bimosiamose disodium after intravenous administration.

G. Wolff, B. Jilma, R. Zahlten, 2005, International journal of clinical pharmacology and therapeutics.

EFFECTS OF THE PAN-SELECTIN ANTAGONIST BIMOSIAMOSE (TBC1269) IN EXPERIMENTAL HUMAN ENDOTOXEMIA

G. Wolff, J. Leitner, B. Jilma, 2007, Shock.

Bimosiamose, an inhaled small-molecule pan-selectin antagonist, attenuates late asthmatic reactions following allergen challenge in mild asthmatics: a randomized, double-blind, placebo-controlled clinical cross-over-trial.

G. Wolff, R. Buhl, K. Beeh, 2006, Pulmonary pharmacology & therapeutics.

Tolerability and pharmacokinetics of inhaled bimosiamose disodium in healthy males.

G. Wolff, B. Jilma, K. Beeh, 2007, British journal of clinical pharmacology.

Rational design of novel, potent small molecule pan-selectin antagonists.

G. Wolff, B. Heinemann, R. Kranich, 2007, Journal of medicinal chemistry.